Immunization with interleukin-2-secreting allogeneic cells transfected with DNA from mouse melanoma cells induces immune responses that prolong the lives of mice with melanoma

Cancer Gene Therapy

Volumn 5, Issue 2, 1998, Pages 110-118

  Sun, Tiedan ^a   Carr Brendel, Victoria ^a   De Zoeten, Edwin F ^a   Cohen, Edward P ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Immunity; Melanoma; Mutations; Transfected cells; Tumor DNA; UV irradiation

Indexed keywords

CANCER VACCINE; DNA; INTERLEUKIN 2; OUABAIN;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; CELL LINE; CYTOTOXIC T LYMPHOCYTE; DRUG RESISTANCE; EXPERIMENTAL MELANOMA; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; MOUSE; RADIATION EXPOSURE; SECRETION; SURVIVAL; ULTRAVIOLET RADIATION;

ANIMALS; CANCER VACCINES; CELL LINE; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OUABAIN; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED; ULTRAVIOLET RAYS;

EID: 0032018222     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Pardoll DM. New strategies for active immunotherapy with genetically engineered tumor cells. Curr Opin Immunol. 1992;4:619-623.
2. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Combined vaccination with major histocompatibility class I and interleukin-2. Cancer Res. 1995;55:4941-4949.
3. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol. 1992;10:180-199.
4. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI. Interleukin-2 production by tumor cells by-passes T helper function in the generation of an antitumor response. Cell. 1990;60:397-403.
5. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
6. McAdam AJ, Felcher A, Woods ML, et al. Transfection of transforming growth factor-β producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes. J Immunother. 1994;15:155-164.
7. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
8. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science. 1992;257:548-551.
9. Mullen CA, Coale MM, Levy AT, et al. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res. 1992;52:6020-6024.
10. Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992;52:3679-3686.
11. McBride WH, Thacker JD, Comora S, et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res. 1992;52:3931-3937.
12. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamanstein T, Blankenstein T. Mechanism of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA. 1993;90:2774-2778.
13. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 1990;50:7820-7825.
14. + T cells against the wildtype tumor: correlation with antigen presentation capability. J Exp Med. 1992;175:1423-1431.
15. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
16. + cells. Int J Cancer. 1996;28:42-47.
17. Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol. 1996;156:1095-1100.
18. Gajewski TF, Renauld JC, Van Pel A, Boon T. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol. 1995;154:5637-5648.
19. Coulie PG, Lehmann F, Lethe B, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA. 1995;92:7976-7980.
20. Boon T, Van den Eynde B, Hirsch H, et al. Genes coding for tumor-specific rejection antigens. Cold Spring Harbor Symp Quant Biol. 1994;59:617-622.
21. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995;2:167-175.
22. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 1995;182:689-698.
23. De Smet C, Courtois SJ, Faraoni I, et al. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics. 1995;42:282-290.
24. van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994;24: 3038-3043.
25. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993;178:489-495.
26. Brichard VG, Herman J, Van Pel A, et al. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol. 1996;26:224-230.
27. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytotoxic T-cells specific for peptides derived from the Her-2/Neu proto-oncogene protein. Cancer Res. 1994;54:1071-1076.
28. Van den Eynde B, Gaugler B, van der Bruggen P, Coulie P, Brichard V, Boon T. Human tumor antigens recognized by T-cells: perspectives for new cancer vaccines. Biochem Soc Trans. 1995;23:681-686.
29. Kim TS, Russell SJ, Collins MKL, Cohen EP. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma. Int J Cancer. 1993;55: 865-862.
30. Kim TS, Cohen EP. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res. 1994;54:2531-2535.
31. Sun T, Kim TS, Waltz MR, Cohen EP. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice. Cancer Gene Ther. 1995;2:183-190.
32. Russell SJ, Eccles SA, Flemming CL, Johnson CA, Collins MKL. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer. 1991;47:244-251.
33. Colbere-Garapin F, Horodniceanu F, Kourilsky P, Garapin A. A new dominant hybrid selective marker for eucaryotic cells. J Mol Biol. 1981;150:1-14.
34. Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and quantitative microassay for activity. J Immunol. 1978;120:2027-2032.
35. Nairn RS, Mitchell DL, Adair GM, Thompson LH, Siciliano MJ. UV mutagenesis, cytotoxicity and split dose recovery in a human-CHO cell hybrid have inter-mediate (6-4) photoproduct repair. Mutat Res. 1989; 217:193-201.
36. Nair SK, Boczkowski D, Snyder D, Gilboa E. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol. 1997; 27:589-597.
37. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;84:465-472.